CYP2B6 and bupropion's smoking‐cessation pharmacology: the role of hydroxybupropion AZX Zhu, LS Cox, N Nollen, B Faseru, KS Okuyemi, JS Ahluwalia, ... Clinical Pharmacology & Therapeutics 92 (6), 771-777, 2012 | 108* | 2012 |
Effects of menthol on nicotine pharmacokinetic, pharmacology and dependence in mice SD Alsharari, JR King, JC Nordman, PP Muldoon, A Jackson, AZX Zhu, ... PloS one 10 (9), e0137070, 2015 | 102 | 2015 |
The ability of plasma cotinine to predict nicotine and carcinogen exposure is altered by differences in CYP2A6: the influence of genetics, race, and sex AZX Zhu, CC Renner, DK Hatsukami, GE Swan, C Lerman, NL Benowitz, ... Cancer epidemiology, biomarkers & prevention 22 (4), 708-718, 2013 | 96 | 2013 |
Cannabinoid receptor stimulation increases motivation for nicotine and nicotine seeking I Gamaleddin, C Wertheim, AZX Zhu, KM Coen, K Vemuri, A Makryannis, ... Addiction biology 17 (1), 47-61, 2012 | 96 | 2012 |
Physiologically‐based pharmacokinetic modeling in renal and hepatic impairment populations: a pharmaceutical industry perspective T Heimbach, Y Chen, J Chen, V Dixit, N Parrott, SA Peters, I Poggesi, ... Clinical Pharmacology & Therapeutics 110 (2), 297-310, 2021 | 72 | 2021 |
Influence of CYP2B6 genetic variants on plasma and urine concentrations of bupropion and metabolites at steady state NL Benowitz, AZX Zhu, RF Tyndale, D Dempsey, P Jacob III Pharmacogenetics and genomics 23 (3), 135-141, 2013 | 69 | 2013 |
Alaska Native smokers and smokeless tobacco users with slower CYP2A6 activity have lower tobacco consumption, lower tobacco-specific nitrosamine exposure and lower tobacco … AZX Zhu, MJ Binnington, CC Renner, AP Lanier, DK Hatsukami, ... Carcinogenesis 34 (1), 93-101, 2013 | 58 | 2013 |
Pharmacogenetics of drug dependence: role of gene variations in susceptibility and treatment JY Khokhar, CS Ferguson, AZX Zhu, RF Tyndale Annual review of pharmacology and toxicology 50, 39-61, 2010 | 58 | 2010 |
Fasiglifam (TAK-875) alters bile acid homeostasis in rats and dogs: a potential cause of drug induced liver injury FS Wolenski, AZX Zhu, M Johnson, S Yu, Y Moriya, T Ebihara, ... Toxicological Sciences 157 (1), 50-61, 2017 | 56 | 2017 |
Association of CHRNA5‐A3‐B4 SNP rs2036527 With Smoking Cessation Therapy Response in African‐American Smokers AZX Zhu, Q Zhou, LS Cox, SP David, JS Ahluwalia, NL Benowitz, ... Clinical Pharmacology & Therapeutics 96 (2), 256-265, 2014 | 54 | 2014 |
Quantitative systems pharmacology approaches for immuno‐oncology: adding virtual patients to the development paradigm V Chelliah, G Lazarou, S Bhatnagar, JP Gibbs, M Nijsen, A Ray, B Stoll, ... Clinical Pharmacology & Therapeutics 109 (3), 605-618, 2021 | 51 | 2021 |
Genome-wide meta-analysis of cotinine levels in cigarette smokers identifies locus at 4q13. 2 JJ Ware, X Chen, J Vink, A Loukola, C Minica, R Pool, Y Milaneschi, ... Scientific reports 6 (1), 20092, 2016 | 50 | 2016 |
Genome‐wide association study of a nicotine metabolism biomarker in African American smokers: impact of chromosome 19 genetic influences MJ Chenoweth, JJ Ware, AZX Zhu, CB Cole, LS Cox, N Nollen, ... Addiction 113 (3), 509-523, 2018 | 48 | 2018 |
Novel CYP2A6 variants identified in African Americans are associated with slow nicotine metabolism in vitro and in vivo M Piliguian, AZX Zhu, Q Zhou, NL Benowitz, JS Ahluwalia, LS Cox, ... Pharmacogenetics and genomics 24 (2), 118-128, 2014 | 47 | 2014 |
CYP2A6 and CYP2B6 genetic variation and its association with nicotine metabolism in South Western Alaska Native people MJ Binnington, AZX Zhu, CC Renner, AP Lanier, DK Hatsukami, ... Pharmacogenetics and genomics 22 (6), 429-440, 2012 | 47 | 2012 |
Lack of Associations of CHRNA5-A3-B4 Genetic Variants with Smoking Cessation Treatment Outcomes in Caucasian Smokers despite Associations with Baseline … RF Tyndale, AZX Zhu, TP George, P Cinciripini, LW Hawk Jr, RA Schnoll, ... PloS one 10 (5), e0128109, 2015 | 46 | 2015 |
Variation in trans-3′-hydroxycotinine glucuronidation does not alter the nicotine metabolite ratio or nicotine intake AZX Zhu, Q Zhou, LS Cox, JS Ahluwalia, NL Benowitz, RF Tyndale PLoS One 8 (8), e70938, 2013 | 44 | 2013 |
Effects of methoxsalen, a CYP2A5/6 inhibitor, on nicotine dependence behaviors in mice D Bagdas, PP Muldoon, AZX Zhu, RF Tyndale, MI Damaj Neuropharmacology 85, 67-72, 2014 | 40 | 2014 |
Recommendations for the design of clinical drug–drug interaction studies with itraconazole using a mechanistic physiologically‐based pharmacokinetic model Y Chen, TD Cabalu, E Callegari, H Einolf, L Liu, N Parrott, SA Peters, ... CPT: Pharmacometrics & Systems Pharmacology 8 (9), 685-695, 2019 | 32 | 2019 |
Quantitative translational modeling to facilitate preclinical to clinical efficacy & toxicity translation in oncology AZX Zhu Future science OA 4 (5), FSO306, 2018 | 32 | 2018 |